Results 41 to 50 of about 4,731,201 (386)

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

open access: yesNew England Journal of Medicine, 2015
BACKGROUND The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
B. Zinman   +11 more
semanticscholar   +1 more source

Cardiovascular rehabilitation

open access: yesAnnals of Physical and Rehabilitation Medicine, 2017
no ...
Grémeaux, Vincent, Casillas, Jean-Marie
openaire   +3 more sources

The light and shadow of senescence and inflammation in cardiovascular pathology and regenerative medicine [PDF]

open access: yes, 2017
Recent epidemiologic studies evidence a dramatic increase of cardiovascular diseases, especially associated with the aging of the world population. During aging, the progressive impairment of the cardiovascular functions results from the compromised ...
Cavarretta, Elena   +9 more
core   +4 more sources

Cardiovascular Genomics [PDF]

open access: yesJournal of Nursing Scholarship, 2013
AbstractPurpose: This article provides an update on cardiovascular genomics using three clinically relevant exemplars, including myocardial infarction (MI) and coronary artery disease (CAD), stroke, and sudden cardiac death (SCD).Organizational Construct: Recent advances in cardiovascular genomic research, testing, and clinical implications are ...
Kathleen T. Hickey   +3 more
openaire   +3 more sources

Impact of Cardiovascular Diseases on Ischemic Stroke Outcomes

open access: yesJournal of Integrative Neuroscience, 2022
Stroke induces complex pathological cascades in the affected brain area, leading to brain injury and functional disability. To fight against cerebral ischemia/reperfusion-induced neuronal death, numerous neuroprotective strategies and reagents have been ...
Christa C. Huber   +2 more
doaj   +1 more source

C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease [PDF]

open access: yes, 2003
C-reactive protein (CRP) has been proposed as a risk factor for cardiovascular disease; however, this association is confounded by mutual relationships with both classical and haematological cardiovascular risk factors. We, therefore, measured CRP with a
Ann Rumley   +31 more
core   +1 more source

Cardiovascular regeneration [PDF]

open access: yesStem Cell Research & Therapy, 2014
Heart disease remains the number one cause of death in developed countries. Loss of cardiomyocytes (CMs) due to aging or pathophysiological conditions (for example, myocardial infarction) is generally considered irreversible, and can lead to lethal conditions from cardiac arrhythmias to heart failure.
openaire   +2 more sources

Hemodynamic response to thermal stress varies with sex and age: a murine MRI study

open access: yesInternational Journal of Hyperthermia, 2022
Purpose The cardiovascular (CV) system plays a vital role in thermoregulation because of its influence on heat transfer via forced convection and conduction by changes in blood distribution, blood velocity, and proximity of vessels to surrounding tissues.
A. Colleen Crouch   +2 more
doaj   +1 more source

Evaluation of liver fibrosis and carotid intima-media thickness index (C-IMT) in patients with chronic hepatitis C virus before and after direct-acting antiviral treatment (DAA) [PDF]

open access: yesRomanian Journal of Infectious Diseases, 2021
Introduction. Viral hepatitis is still a challenge for the medical world and research over the past decades has been aimed at discovering viable methods of prevention, diagnosis and treatment. Material and methods.
Raluca Mihaela Dirtu   +8 more
doaj   +1 more source

Riesgo al suspender el antiagregante en el perioperatorio: Ensayo clínico

open access: yesRevista Electrónica de AnestesiaR, 2010
La aspirina ha venido usándose durante décadas como prevención secundaria del infarto de miocardio o del ictus en pacientes con cardiopatía isquémica o enfermedad cerebrovascular conocida. El tratamiento antiagregante se asocia a una reducción del riesgo
Carlos Castro Arranz
doaj   +1 more source

Home - About - Disclaimer - Privacy